StreetAlpha.app
Home › Stocks › PALI

Palisade Bio, Inc. (PALI)

Healthcare
$1.01
▼ −1.94%
LAST CLOSE · NOV 17

Palisade Bio develops oral drug candidates for inflammatory bowel disease, led by PALI-2108 for ulcerative colitis and Crohn's disease. It last closed at $1.01 on Nov 17, down 1.94% on the day. The average 12-month price target from 3 analysts is $9.00 (+791.1% from the last close), with a high of $16.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is PALI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$500K
Net income
−$43.7M
−8739.2% margin
Operating margin
−9625.4%
−$48.1M operating income
Valuation
Market cap
$181.1M
179.3M shares
P/E
–
Price to sales
362.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$113.6M
At Sep 30
Shareholder equity
$112.4M
Shares outstanding
179.3M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $250K$250KFY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From PALI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on PALI in the past 90 days
Average 12-month target
$9.00
▲ 791.1% upside

Based on 3 analysts who set a price target on PALI in the past 90 days. The average target is $9.00, with a high of $16.00 and a low of $5.00, compared with the last close of $1.01.

Low $5.00Avg $9.00High $16.00
Blue marker: last close $1.01
Highest target$16.00
Average target$9.00
Lowest target$5.00
Latest rating changes
Piper SandlerMaintained
Nov 11Buy$16
HC Wainwright & Co.Target lowered
Nov 11Buy$7 → $5
HC Wainwright & Co.Reiterated
Oct 13Buy$7
Raymond JamesInitiated
Oct 9Buy$6
OppenheimerInitiated
Jul 23Buy$8
DateFirmActionRatingPrice target
Nov 11Piper SandlerMaintainedBuy$16
Nov 11HC Wainwright & Co.Target loweredBuy$7 → $5
Oct 13HC Wainwright & Co.ReiteratedBuy$7
Oct 9Raymond JamesInitiatedBuy$6
Jul 23OppenheimerInitiatedBuy$8
Loading…

Technical Analysis

PALI · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 18% below its 20 day and 42% below its 50 day average. It is 80% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the 52 week low at $0.99, and the nearest resistance the Pivot R1 at $1.03.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.5%/day
Key levels
$2.8652 week high+183.2%
$1.82200 day average+80.2%
$1.73100 day average+71.3%
$1.4450 day average+42.6%
$1.30Swing high (Nov 4)+28.7%
$1.1920 day average+17.8%
$1.03Pivot R1+2.0%
$1.01Pivot+0.0%
$1.01Last close
$0.9952 week low−2.0%
$0.99Pivot S1−2.0%
Indicators
RSI (14)32.38Weak, oversold below 30Neutral
MACD-0.11Below its signal lineBearish
Stochastic10.0Near the bottom of its rangeOversold
ADX (14)40.2Strong downtrend
Williams %R-93.5Oversold below −80, overbought above −20Oversold
CCI (20)-167.0Oversold below −100, overbought above 100Oversold
Rate of change−17.9%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 9.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PALI

What happened before

See how PALI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PALI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PALI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PALI in the last 90 days.

Loading…

See today’s whale options flow across the market →

PALI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●57 buying vs 53 selling
  • ▲Held by funds +2.5 pts
  • ▼Funds holding -8
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding116124−6.5%
In funds' top 10110.0%
Held by funds99.2%96.7%+2.5 pts
New / increased17 / 4049 / 33−30.5%
Reduced / sold out28 / 2524 / 21+17.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PALI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PALI is in one of them and how their past PALI trades turned out.

PALI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PALI in an article yet. Here's the latest on the wider market.

About Palisade Bio

Palisade Bio is a biopharmaceutical company based in Carlsbad, California, that is developing oral medicines for inflammatory bowel disease. Its lead candidate, PALI-2108, is a pill taken once a day that stays inactive until it reaches the lower intestine, where gut bacteria convert it into an active drug at sites of inflammation. The company is testing the candidate in people with ulcerative colitis and Crohn's disease. Its candidates are still in clinical testing and are not yet on the market.

Headquarters
Carlsbad, CA